Product Information

CEVIMELINE HCL 30 MG CAPSULE is a generic product labeled by Advagen Pharma Ltd., priced at $0.6380 per EA under NDC 72888011801. Its NADAC has been published 164 times since Oct 4, 2023.

FDA first approved this application on Apr 6, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

CEVIMELINE HCL 30 MG CAPSULE

CEVIMELINE HYDROCHLORIDE
$0.6380per EA

Strength

30 mg/1

NDC

72888011801

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

CEVIMELINE HYDROCHLORIDE

Approval Type

Generic (ANDA)

FDA Application

ANDA216682

FDA Approved

4/6/2023

TE Code

AB

On Market Since

4/6/2023

Pharmacological Classes

Cholinergic Muscarinic Agonists
Cholinergic Receptor Agonist

Price Statistics

The NADAC for CEVIMELINE HCL 30 MG CAPSULE has been published 164 times since Oct 4, 2023, and over the history we have for it it has declined 45.5%. The table below summarizes its recorded NADAC range and movement.

Current price$0.6380 per EA
All-time high$1.1715 (Oct 11, 2023)
All-time low$0.6268 (Nov 20, 2024)
52-week high$0.7289
52-week low$0.6380
Median price$0.7165
Average price$0.8007
Largest weekly change-27.7% (Nov 20, 2024)
Weeks tracked164
Tracking sinceOct 4, 2023

Price History

1W

-11.9%

1M

-12.5%

3M

-9.9%

6M

-10.8%

1Y

-9.6%

3Y

-43.8%

5Y

N/A

All

-45.5%

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of CEVIMELINE HCL 30 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for CEVIMELINE HCL 30 MG CAPSULE, manufactured by Advagen Pharma Ltd., is $0.6380 per EA (NDC 72888011801), effective Nov 18, 2026.

How has the price of CEVIMELINE HCL 30 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for CEVIMELINE HCL 30 MG CAPSULE has declined 45.5%. It has been tracked across 164 weekly CMS publications since Oct 4, 2023.

What are the highest and lowest recorded NADAC prices for CEVIMELINE HCL 30 MG CAPSULE?

Since Oct 4, 2023, the NADAC for CEVIMELINE HCL 30 MG CAPSULE has ranged from a low of $0.6268 (Nov 20, 2024) to a high of $1.1715 (Oct 11, 2023), with a median of $0.7165 per EA.

Are there cheaper alternatives to CEVIMELINE HCL 30 MG CAPSULE?

2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CEVIMELINE HCL 30 MG CAPSULE in a comparable dosage form, but none are currently priced below it.

Who manufactures CEVIMELINE HCL 30 MG CAPSULE?

CEVIMELINE HCL 30 MG CAPSULE (NDC 72888011801) is labeled by Advagen Pharma Ltd., and CMS classifies it as a generic product.